Russia completes early trials of second potential Covid-19 vaccine

Russia completes early trials of second potential Covid-19 vaccine

PanARMENIAN.Net - Siberia’s Vector virology institute on Tuesday, September 8 completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.

Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August. Late-stage trials of this vaccine, due to involve 40,000 participants, were launched last week, Reuters says.

Human trials of the second potential Covid-19 vaccine, a peptide-based jab, began on July 27 and involved a group of 100 volunteers, Interfax cited watchdog Rospotrebnadzor as saying.

“Today ... the final group of 20 volunteers was released from hospital,” said in a statement. “All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good.”

Results are due to be published on September 30, Interfax said.

 Top stories
Azerbaijani authorities report that they have already resettled 3,000 people in the Nagorno-Karabakh town of Stepanakert.
On June 10, Azerbaijani President of Azerbaijan Ilham Aliyev will leave for Turkey on a working visit.
Azerbaijani President Ilham Aliyev arrived in Moscow on April 22 to hold talks with Russian counterpart Vladimir Putin.
Authorities said a total of 192 Azerbaijani troops were killed and 511 were wounded during Azerbaijan’s offensive.
Partner news
---